The Efficacy of Nasyakarma and Snehapana in the Management of Migraine: A Randomized, Open-label, Parallel-group, Clinical Trial
Abstract
This clinical trial was designed to determine and compare the efficacy of two treatment modalities,
Nasyakarma
(Nasal therapy) and
Snehapana
(Oral administration), using
Vrihatajivakadya Taila
(~a medicated oil) for the management of
Ardhavbhedaka
(~migraine).
This was a randomized, open-label, parallel-group, clinical trial. Sixty clinically diagnosed migraine patients were randomly assigned to either the
Nasyakarma
or the
Snehapana
. The
Nasya Karma
group received ~0.5 ml of
Vrihatajivakadya Taila
per nostril daily, while the
Sneha Pana
group received ~24 ml of the same oil orally after food in the evening for 14 days. The primary and secondary outcomes were to measure the changes in the migraine disability assessment scores (MIDAS) and migraine-specific quality of life scores, respectively.
The Wilcoxon matched-pairs signed-rank test and the Mann–Whitney test were used for statistical analysis. The statistical significance level was set as significant at a 5% level (
P
< 0.05).
Both treatment groups demonstrated significant improvements in MIDAS and quality of life scores. However, the
Nasyakarma
group showed more improvement than the
Snehapana
group. Changes in MIDAS and migraine-specific quality of life scores were 2.533 ± 1.852 and 9.100 ± 5.268 in the
Nasyakarma
group and 1.600 ± 1.940 and 6.067 ± 5.564 in the
Snehapana
group, respectively. No serious adverse events (AEs) were reported in either group, and AEs were not related to the treatments.
Nasyakarma
and…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.